Eligible patients were randomly assigned ( 1:1 ) to receive either mFOLFOX6 plus bevacizumab ( on day 1 of each 2-week cycle , 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m ( 2 ) oxaliplatin , 200 mg/m ( 2 ) l-leucovorin , 400 mg/m ( 2 ) bolus fluorouracil , and 2400 mg/m ( 2 ) infusional fluorouracil ) or SOX plus bevacizumab ( on day 1 of each 3-week cycle , 75 mg/kg intravenous infusion of bevacizumab and 130 mg/m ( 2 ) intravenous infusion of oxaliplatin ; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15 , followed by 7-day break ) .